Durham, NC (PRWEB) October 09, 2013
Registration is now open for the Society for Translational Oncology (STO) 2013 Chabner Colloquium: Collaboration in Cancer Trials. The continuing medical education (CME) symposium is jointly sponsored by The Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO's official journal. The meeting will be held October 28-29, 2013 at the Starr Center at Schepens Eye Research Institute in Boston, Massachusetts.
The symposium will focus on presenting updates on promising targets for development of new cancer treatments. Researchers, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to view the agenda, confirmed faculty, and register online at http://bit.ly/STO-MGH-CC2013.
Offered for the third year, the 2013 Chabner Colloquium includes presentations on emerging molecular and genetic targets for cancer treatments—with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. research centers will provide informative updates on their work.
The meeting is named for Dr. Bruce A. Chabner, Director of Clinical Research at Massachusetts General, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states that “It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."
Monday’s session topics focus on addressing resistance to targeted therapy, as well as exploring the biology of unique tumors and drug development based on new signaling pathways.
A highlight of Monday’s agenda includes a lecture by Dr. Louis Staudt, Head of the Molecular Biology of Lymphoid Malignancies Section and Deputy Branch Chief of the Center for Cancer Research, National Cancer Institute, who will provide an update in “New Lymphoma Therapies Inspired by Functional and Structural Genomics.” The program also incorporates a Monday afternoon forum with junior faculty members from Dana-Farber/Harvard Cancer Center.
Tuesday’s session topics include lectures on biology and treatment in melanoma and breast cancer, as well as an update on stem cells and circulating tumor cells. Day 2 will also feature a special symposium titled Prostate Cancer: Progress and Promise, Part IV which will highlight CTC developments, neoadjuvant therapy and novel agents in advanced disease.
Four video CME activities and written summaries will be derived from the special symposium presentations and the roundtable discussion.
The videos will also be made available online in STO’s media library (http://www.STO-online.org/medialibrary) and in The Oncologist mobile app.
STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This two day symposium will be designated for a maximum of 12 AMA PRA Category 1 Credit(s)™.
For more information or to register, go to http://bit.ly/STO-MGH-CC2013.
# # #
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://www.sto-online.org.
About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its eighteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.
About The Massachusetts General Hospital Cancer Center
A Comprehensive Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
Known for providing customized, innovative treatments and compassionate care to both adults and children, the Massachusetts General Hospital Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services.
The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.